Verici Dx Plc (LON:VRCI)
0.38p
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Serial dilution erodes shareholder value; cash burn outpaces revenue with no clear path to self-funding.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, in…
- Sector:
- Healthcare
- Industry:
- Diagnostics & Research
- Market Cap:
- £8.9M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Verici Dx Plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free